Commentary|Podcasts|November 19, 2026

Supplements and Featured Publications

  • Summarizing Clinical Advances in the Management of MET Exon 14 Skipping Mutated–NSCLC
  • Volume 1
  • Issue 1

Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC

Fact checked by: Chris Ryan, Sidharth Rastogi

Paul K. Paik, MD, discusses long-term responses to tepotinib in patients with advanced NSCLC harboring MET exon 14 skipping alterations.



Welcome to OncLive On Air®! I’m your host today, Chris Ryan.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with Paul K. Paik, MD, about long-term responses to tepotinib (Tepmetko) in patients with advanced non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Paik is clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, New York.

In our exclusive interview, Dr Paik discussed a subset analysis of the phase 2 VISION trial (NCT02864992) presented at the 2026 ASCO Annual Meeting that profiled patients with long-term responses to tepotinib. Additionally, he explained where patients with MET exon 14 skipping alterations are missed in clinical practice and how he chooses among MET inhibitors and positions them relative to immunotherapy. Finally, Dr Paik shared his approach to managing peripheral edema and other adverse effects (AEs) of selective MET inhibitors.

In VISION, 8.3% of patients (n = 313) with MET exon 14 skipping NSCLC achieved a duration of response to tepotinib longer than 36 months (range, 36.6-78.9) as of the May 20, 2024, data cutoff; their median duration of treatment was 50.7 months (range, 15.9-83.1). Dr Paik noted that these patients were largely similar to the overall population in their clinical characteristics and co-alterations; high-level MET amplification was found in 13.6% of patients with available sequencing data (n = 22). Of the 12 long-term responders who discontinued tepotinib, 5 did so because of AEs. Four patients who stopped early because of AEs prior to progression had responses that continued for up to 52 months without further anticancer therapy, which Dr Paik said points to biology worth studying to extend responses in other patients.

In the overall VISION population after at least 3 years of follow-up, tepotinib generated an objective response rate of 51.8% (95% CI, 46.1%-57.4%) and a median overall survival of 19.7 months (95% CI, 16.2-22.3). Dr Paik favors first-line use, citing limited data on immunotherapy in this older population and retrospective data suggesting poor responses to immunotherapy despite frequently high PD-L1 expression. To manage edema, he described holding tepotinib, sometimes for weeks, before restarting, potentially at a reduced dose.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.


Related to this article